BACKGROUND: Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is an established procedure for the pathological diagnosis of gastrointestinal submucosal tumors (SMTs). Although bleeding and perforation are potentially severe complications of EUS-FNA, the incidences and severities of these complications have not yet been fully evaluated because of their relative rarity. AIM: The purpose of this study was to evaluate the incidences and mortality of severe bleeding and perforation in patients who underwent EUS-FNA for SMTs. METHODS: The records of 1,135 consecutive patients who underwent EUS-FNA for SMTs at 219 hospitals, with low- to high-volume, were reviewed using a Japanese nationwide administrative database. RESULTS: Of the targeted lesions 73.5% were located in the stomach, 13.4% in the esophagus, 8.2% in the duodenum, and 4.9% at other sites. Five patients (0.44%) experienced severe bleeding requiring red blood cell transfusion or endoscopic treatment, with none experiencing perforation. Only one patient (0.09%) died in-hospital within 30 days of EUS-FNA (0.09%), with death not associated with bleeding or perforation. CONCLUSIONS: EUS-FNA is safe in evaluating SMTs, with low risks of bleeding and perforation.
BACKGROUND: Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is an established procedure for the pathological diagnosis of gastrointestinal submucosal tumors (SMTs). Although bleeding and perforation are potentially severe complications of EUS-FNA, the incidences and severities of these complications have not yet been fully evaluated because of their relative rarity. AIM: The purpose of this study was to evaluate the incidences and mortality of severe bleeding and perforation in patients who underwent EUS-FNA for SMTs. METHODS: The records of 1,135 consecutive patients who underwent EUS-FNA for SMTs at 219 hospitals, with low- to high-volume, were reviewed using a Japanese nationwide administrative database. RESULTS: Of the targeted lesions 73.5% were located in the stomach, 13.4% in the esophagus, 8.2% in the duodenum, and 4.9% at other sites. Five patients (0.44%) experienced severe bleeding requiring red blood cell transfusion or endoscopic treatment, with none experiencing perforation. Only one patient (0.09%) died in-hospital within 30 days of EUS-FNA (0.09%), with death not associated with bleeding or perforation. CONCLUSIONS: EUS-FNA is safe in evaluating SMTs, with low risks of bleeding and perforation.
Authors: Michelle A Anderson; Tamir Ben-Menachem; S Ian Gan; Vasundhara Appalaneni; Subhas Banerjee; Brooks D Cash; Laurel Fisher; M Edwyn Harrison; Robert D Fanelli; Norio Fukami; Steven O Ikenberry; Rajeev Jain; Khalid Khan; Mary Lee Krinsky; David R Lichtenstein; John T Maple; Bo Shen; Laura Strohmeyer; Todd Baron; Jason A Dominitz Journal: Gastrointest Endosc Date: 2009-11-03 Impact factor: 9.427
Authors: Joseph J Y Sung; James Y W Lau; Jessica Y L Ching; Justin C Y Wu; Yuk T Lee; Philip W Y Chiu; Vincent K S Leung; Vincent W S Wong; Francis K L Chan Journal: Ann Intern Med Date: 2009-11-30 Impact factor: 25.391
Authors: Fauze Maluf-Filho; Joel Fernandez de Oliveira; Ernesto Quaresma Mendonça; Augusto Carbonari; Bruno Antônio Maciente; Bruno Chaves Salomão; Bruno Frederico Medrado; Carlos Marcelo Dotti; César Vivian Lopes; Cláudia Utsch Braga; Daniel Alencar M Dutra; Felipe Retes; Frank Nakao; Giovana Biasia de Sousa; Gustavo Andrade de Paulo; Jose Celso Ardengh; Juliana Bonfim Dos Santos; Luciana Moura Sampaio; Luciano Okawa; Lucio Rossini; Manoel Carlos de Brito Cardoso; Marco Antonio Ribeiro Camunha; Marcos Clarêncio; Marcos Eduardo Lera Dos Santos; Matheus Franco; Nutianne Camargo Schneider; Ramiro Mascarenhas; Rodrigo Roda; Sérgio Matuguma; Simone Guaraldi; Viviane Figueiredo Journal: Endosc Ultrasound Date: 2017 Nov-Dec Impact factor: 5.628